- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr John Thompson Outlines Updates in Melanoma
John A. Thompson, MD, co-director of the Melanoma Clinic at the Seattle Cancer Care Alliance, highlighted the major points of his melanoma talk at the National Comprehensive Cancer Network’s 21st Annual Meeting, including the FDA approval of new drugs and the development of new viral therapies.
John A. Thompson, MD, co-director of the Melanoma Clinic at the Seattle Cancer Care Alliance, highlighted the major points of his melanoma talk at the National Comprehensive Cancer Network’s 21st Annual Meeting, including the FDA approval of new drugs and the development of new viral therapies.
Transcript (slightly modified)
What are some of the key takeaways from your session “Major Changes in Systemic Therapy for Advanced Melanoma” at the NCCN Annual Meeting?
The area of melanoma has been changing very rapidly and just in the past year a lot has changed. Today I provided updates with longer follow-up to some of the studies of immune checkpoint therapy for melanoma.
I highlighted the recent FDA approval of the combination of ipilimumab and nivolumab, which yields a higher response rate than either agent alone. Unfortunately, a higher toxicity rate also, but we discussed how the toxicity is identified and treated.
I talked about a new form of immunotherapy, which is a first example of oncolytic viral therapy using the agent T-VEC. This is a genetically modified virus that is injected into melanoma tumors and causes death of some of the melanoma cells and also triggers an immune response to the melanoma. So that’s an interesting and new form of immunotherapy.
And then I also updated the results with the molecularly targeted therapies, that is drugs that target mutations in BRAF.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
